Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM2B | Q8NHM5 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026598 | 0.98 | SIGMAR1 (0.53) | SIGMAR1L3MBTL3L3MBTL1KDM2BKMT2A | |
| SCHEMBL10169301 | 0.95 | KDM2B (0.53) | SIGMAR1L3MBTL3L3MBTL1KDM2BKMT2A | |
| SCHEMBL10169300 | 0.92 | KMT2A (0.53) | SIGMAR1L3MBTL3L3MBTL1KDM2BKMT2A | |
| SCHEMBL14923970 | 0.87 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1KDM2BKMT2AHRH3 | |
| SCHEMBL14923967 | 0.86 | KMT2A (0.51) | SIGMAR1L3MBTL3L3MBTL1KDM2BKMT2A | |
| SCHEMBL17660589 | 0.86 | L3MBTL1 (0.48) | SIGMAR1L3MBTL3L3MBTL1KDM2BKMT2A | |
| SCHEMBL24123752 | 0.85 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1KDM2BKMT2AHRH3 | |
| SCHEMBL14924004 | 0.85 | L3MBTL3 (0.73) | L3MBTL3L3MBTL1KDM2BKMT2AHRH3 | |
| SCHEMBL21731334 | 0.84 | KMT2A (0.47) | SIGMAR1L3MBTL3L3MBTL1KDM2BKMT2A | |
| SCHEMBL25897977 | 0.84 | HRH3 (0.52) | SIGMAR1L3MBTL3L3MBTL1KDM2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-03-02 | — | — | US | disclosed |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HWANG SUNG YEOUN (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | SIGMAR1 4821/4885L3MBTL3 3429/4885L3MBTL1 2596/4885 |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | SIGMAR1 206/4885L3MBTL3 4884/4885L3MBTL1 4883/4885 |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | SIGMAR1 206/4885L3MBTL3 4884/4885L3MBTL1 4883/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | SIGMAR1 4807/4885L3MBTL3 3628/4885L3MBTL1 2790/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | SIGMAR1 4807/4885L3MBTL3 3628/4885L3MBTL1 2790/4885 |
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | ESRRG, ESR1, ESR2 | SIGMAR1 206/4885L3MBTL3 4884/4885L3MBTL1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.